Listed

Arrowhead Pharmaceuticals, Inc.

ARWRNasdaqCIK 879407HealthcareFiscal year ends Sep 30

Latest reported revenue, Q3 FY2026$75.3mRevenue, Q3 FY2026, three months to 2026-06-30$75.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-04, accession 0000879407-26-000057.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 4, 2026.

Latest quarter: Q3 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$75.3mRevenue, Q3 FY2026, three months to 2026-06-30$75.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-04, accession 0000879407-26-000057.Report this figure+171.0% on a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating margin−226.0%Operating margin, Q3 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$170.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-04, accession 0000879407-26-000057.Revenue: $75.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-04, accession 0000879407-26-000057.Report this figure+370.2 pts on a year earlier
  • Net margin−258.2%Net margin, Q3 FY2026, three months to 2026-06-30. net income / revenueNet income: −$194.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-04, accession 0000879407-26-000057.Revenue: $75.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-04, accession 0000879407-26-000057.Report this figure+372.9 pts on a year earlier
  • Diluted EPS−$1.36Diluted EPS, Q3 FY2026, three months to 2026-06-30−$1.36 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-04, accession 0000879407-26-000057.Report this figure−7.9% on a year earlier
  • Free cash flow−$181.3mFree cash flow, Q3 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$177.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-04, accession 0000879407-26-000057. Derived: 9-month figure less the 6-month figure.Capital expenditure: $3.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-04, accession 0000879407-26-000057. Derived: 9-month figure less the 6-month figure.Report this figure−15.4% on a year earlier

Last eight quarters

Full statements
Revenue$75.3mOperating margin −226.0%
Diluted EPS−$1.36, Q3 FY2026
Free cash flow−$181.3m, Q3 FY2026
Arrowhead Pharmaceuticals, Inc., key figures for the last eight quarters
Line itemUnitQ4 FY20242024-09-30Q1 FY20252024-12-31Q2 FY20252025-03-31Q3 FY20252025-06-30Q4 FY20252025-09-30Q1 FY20262025-12-31Q2 FY20262026-03-31Q3 FY20262026-06-30Shape over the periods
Revenue$m0.0Revenue, Q4 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-11-25, accession 0000879407-25-000029. Derived: 12-month figure less the 9-month figure.Report this figure2.5Revenue, Q1 FY2025, three months to 2024-12-31$2.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-02-05, accession 0000879407-26-000034.Report this figure543Revenue, Q2 FY2025, three months to 2025-03-31$542.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0000879407-26-000047.Report this figure27.8Revenue, Q3 FY2025, three months to 2025-06-30$27.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-04, accession 0000879407-26-000057.Report this figure256Revenue, Q4 FY2025, three months to 2025-09-30$256.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-11-25, accession 0000879407-25-000029. Derived: 12-month figure less the 9-month figure.Report this figure264Revenue, Q1 FY2026, three months to 2025-12-31$264.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-02-05, accession 0000879407-26-000034.Report this figure73.7Revenue, Q2 FY2026, three months to 2026-03-31$73.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0000879407-26-000047.Report this figure75.3Revenue, Q3 FY2026, three months to 2026-06-30$75.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-04, accession 0000879407-26-000057.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%not reported (Revenue of zero not reported)(6456.5%)Operating margin, Q1 FY2025, three months to 2024-12-31. operating income / revenueOperating income: −$161.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-02-05, accession 0000879407-26-000034.Revenue: $2.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-02-05, accession 0000879407-26-000034.Report this figure70.2%Operating margin, Q2 FY2025, three months to 2025-03-31. operating income / revenueOperating income: $381.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0000879407-26-000047.Revenue: $542.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0000879407-26-000047.Report this figure(596.2%)Operating margin, Q3 FY2025, three months to 2025-06-30. operating income / revenueOperating income: −$165.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-04, accession 0000879407-26-000057.Revenue: $27.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-04, accession 0000879407-26-000057.Report this figure17.2%Operating margin, Q4 FY2025, three months to 2025-09-30. operating income / revenueOperating income: $44.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-11-25, accession 0000879407-25-000029. Derived: 12-month figure less the 9-month figure.Revenue: $256.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-11-25, accession 0000879407-25-000029. Derived: 12-month figure less the 9-month figure.Report this figure15.5%Operating margin, Q1 FY2026, three months to 2025-12-31. operating income / revenueOperating income: $40.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-02-05, accession 0000879407-26-000034.Revenue: $264.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-02-05, accession 0000879407-26-000034.Report this figure(191.6%)Operating margin, Q2 FY2026, three months to 2026-03-31. operating income / revenueOperating income: −$141.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0000879407-26-000047.Revenue: $73.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0000879407-26-000047.Report this figure(226.0%)Operating margin, Q3 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$170.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-04, accession 0000879407-26-000057.Revenue: $75.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-04, accession 0000879407-26-000057.Report this figure
Net margin%not reported (Revenue of zero not reported)(6923.4%)Net margin, Q1 FY2025, three months to 2024-12-31. net income / revenueNet income: −$173.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-02-05, accession 0000879407-26-000034.Revenue: $2.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-02-05, accession 0000879407-26-000034.Report this figure68.3%Net margin, Q2 FY2025, three months to 2025-03-31. net income / revenueNet income: $370.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-07, accession 0000879407-26-000047.Revenue: $542.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0000879407-26-000047.Report this figure(631.1%)Net margin, Q3 FY2025, three months to 2025-06-30. net income / revenueNet income: −$175.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-04, accession 0000879407-26-000057.Revenue: $27.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-04, accession 0000879407-26-000057.Report this figure(9.3%)Net margin, Q4 FY2025, three months to 2025-09-30. net income / revenueNet income: −$23.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-11-25, accession 0000879407-25-000029. Derived: 12-month figure less the 9-month figure.Revenue: $256.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-11-25, accession 0000879407-25-000029. Derived: 12-month figure less the 9-month figure.Report this figure11.7%Net margin, Q1 FY2026, three months to 2025-12-31. net income / revenueNet income: $30.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-02-05, accession 0000879407-26-000034.Revenue: $264.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-02-05, accession 0000879407-26-000034.Report this figure(180.0%)Net margin, Q2 FY2026, three months to 2026-03-31. net income / revenueNet income: −$132.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-07, accession 0000879407-26-000047.Revenue: $73.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0000879407-26-000047.Report this figure(258.2%)Net margin, Q3 FY2026, three months to 2026-06-30. net income / revenueNet income: −$194.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-04, accession 0000879407-26-000057.Revenue: $75.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-04, accession 0000879407-26-000057.Report this figure
Diluted EPS$ per sharenot reported (Diluted EPS not reported)(1.39)Diluted EPS, Q1 FY2025, three months to 2024-12-31−$1.39 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-02-05, accession 0000879407-26-000034.Report this figure2.75Diluted EPS, Q2 FY2025, three months to 2025-03-31$2.75 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0000879407-26-000047.Report this figure(1.26)Diluted EPS, Q3 FY2025, three months to 2025-06-30−$1.26 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-04, accession 0000879407-26-000057.Report this figurenot reported (Diluted EPS not reported)0.22Diluted EPS, Q1 FY2026, three months to 2025-12-31$0.22 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-02-05, accession 0000879407-26-000034.Report this figure(0.93)Diluted EPS, Q2 FY2026, three months to 2026-03-31−$0.93 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0000879407-26-000047.Report this figure(1.36)Diluted EPS, Q3 FY2026, three months to 2026-06-30−$1.36 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-04, accession 0000879407-26-000057.Report this figure
Free cash flow$m(162)Free cash flow, Q4 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: −$137.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-11-25, accession 0000879407-25-000029. Derived: 12-month figure less the 9-month figure.Capital expenditure: $24.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-11-25, accession 0000879407-25-000029. Derived: 12-month figure less the 9-month figure.Report this figure(154)Free cash flow, Q1 FY2025, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$146.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-02-05, accession 0000879407-26-000034.Capital expenditure: $7.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-02-05, accession 0000879407-26-000034.Report this figure455Free cash flow, Q2 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: $460.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0000879407-26-000047. Derived: 6-month figure less the 3-month figure.Capital expenditure: $5.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0000879407-26-000047. Derived: 6-month figure less the 3-month figure.Report this figure(157)Free cash flow, Q3 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: −$154.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-04, accession 0000879407-26-000057. Derived: 9-month figure less the 6-month figure.Capital expenditure: $2.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-04, accession 0000879407-26-000057. Derived: 9-month figure less the 6-month figure.Report this figure13.0Free cash flow, Q4 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: $20.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-11-25, accession 0000879407-25-000029. Derived: 12-month figure less the 9-month figure.Capital expenditure: $7.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-11-25, accession 0000879407-25-000029. Derived: 12-month figure less the 9-month figure.Report this figure11.3Free cash flow, Q1 FY2026, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $13.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-02-05, accession 0000879407-26-000034.Capital expenditure: $2.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-02-05, accession 0000879407-26-000034.Report this figure81.9Free cash flow, Q2 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: $84.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0000879407-26-000047. Derived: 6-month figure less the 3-month figure.Capital expenditure: $2.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0000879407-26-000047. Derived: 6-month figure less the 3-month figure.Report this figure(181)Free cash flow, Q3 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$177.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-04, accession 0000879407-26-000057. Derived: 9-month figure less the 6-month figure.Capital expenditure: $3.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-04, accession 0000879407-26-000057. Derived: 9-month figure less the 6-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$829.4mOperating margin 11.9%
Diluted EPS−$0.01, FY2025
Free cash flow$156.9m, FY2025
Arrowhead Pharmaceuticals, Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-09-30FY20222022-09-30FY20232023-09-30FY20242024-09-30FY20252025-09-30Shape over the periods
Revenue$m138Revenue, FY2021, twelve months to 2021-09-30$138.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-11-29, accession 0001628280-23-040219.Report this figure243Revenue, FY2022, twelve months to 2022-09-30$243.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-11-26, accession 0001628280-24-049277.Report this figure241Revenue, FY2023, twelve months to 2023-09-30$240.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-11-25, accession 0000879407-25-000029.Report this figure3.6Revenue, FY2024, twelve months to 2024-09-30$3.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-11-25, accession 0000879407-25-000029.Report this figure829Revenue, FY2025, twelve months to 2025-09-30$829.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-11-25, accession 0000879407-25-000029.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%(107.8%)Operating margin, FY2021, twelve months to 2021-09-30. operating income / revenueOperating income: −$149.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2023-11-29, accession 0001628280-23-040219.Revenue: $138.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-11-29, accession 0001628280-23-040219.Report this figure(73.4%)Operating margin, FY2022, twelve months to 2022-09-30. operating income / revenueOperating income: −$178.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-11-26, accession 0001628280-24-049277.Revenue: $243.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-11-26, accession 0001628280-24-049277.Report this figure(85.2%)Operating margin, FY2023, twelve months to 2023-09-30. operating income / revenueOperating income: −$205.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-11-25, accession 0000879407-25-000029.Revenue: $240.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-11-25, accession 0000879407-25-000029.Report this figure(16927.1%)Operating margin, FY2024, twelve months to 2024-09-30. operating income / revenueOperating income: −$601.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-11-25, accession 0000879407-25-000029.Revenue: $3.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-11-25, accession 0000879407-25-000029.Report this figure11.9%Operating margin, FY2025, twelve months to 2025-09-30. operating income / revenueOperating income: $98.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-11-25, accession 0000879407-25-000029.Revenue: $829.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-11-25, accession 0000879407-25-000029.Report this figure
Net margin%(101.9%)Net margin, FY2021, twelve months to 2021-09-30. net income / revenueNet income: −$140.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2023-11-29, accession 0001628280-23-040219.Revenue: $138.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-11-29, accession 0001628280-23-040219.Report this figure(72.4%)Net margin, FY2022, twelve months to 2022-09-30. net income / revenueNet income: −$176.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-11-26, accession 0001628280-24-049277.Revenue: $243.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-11-26, accession 0001628280-24-049277.Report this figure(85.3%)Net margin, FY2023, twelve months to 2023-09-30. net income / revenueNet income: −$205.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-11-25, accession 0000879407-25-000029.Revenue: $240.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-11-25, accession 0000879407-25-000029.Report this figure(16882.4%)Net margin, FY2024, twelve months to 2024-09-30. net income / revenueNet income: −$599.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-11-25, accession 0000879407-25-000029.Revenue: $3.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-11-25, accession 0000879407-25-000029.Report this figure(0.2%)Net margin, FY2025, twelve months to 2025-09-30. net income / revenueNet income: −$1.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-11-25, accession 0000879407-25-000029.Revenue: $829.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-11-25, accession 0000879407-25-000029.Report this figure
Diluted EPS$ per share(1.36)Diluted EPS, FY2021, twelve months to 2021-09-30−$1.36 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2023-11-29, accession 0001628280-23-040219.Report this figure(1.67)Diluted EPS, FY2022, twelve months to 2022-09-30−$1.67 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-11-26, accession 0001628280-24-049277.Report this figure(1.92)Diluted EPS, FY2023, twelve months to 2023-09-30−$1.92 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-11-25, accession 0000879407-25-000029.Report this figure(5.00)Diluted EPS, FY2024, twelve months to 2024-09-30−$5.00 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-11-25, accession 0000879407-25-000029.Report this figure(0.01)Diluted EPS, FY2025, twelve months to 2025-09-30−$0.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-11-25, accession 0000879407-25-000029.Report this figure
Free cash flow$m148Free cash flow, FY2021, twelve months to 2021-09-30. operating cash flow − capital expenditureOperating cash flow: $171.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2023-11-29, accession 0001628280-23-040219.Capital expenditure: $23.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2023-11-29, accession 0001628280-23-040219.Report this figure(189)Free cash flow, FY2022, twelve months to 2022-09-30. operating cash flow − capital expenditureOperating cash flow: −$136.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-11-26, accession 0001628280-24-049277.Capital expenditure: $52.8m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-11-26, accession 0001628280-24-049277.Report this figure(331)Free cash flow, FY2023, twelve months to 2023-09-30. operating cash flow − capital expenditureOperating cash flow: −$153.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-11-25, accession 0000879407-25-000029.Capital expenditure: $176.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-11-25, accession 0000879407-25-000029.Report this figure(604)Free cash flow, FY2024, twelve months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: −$462.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-11-25, accession 0000879407-25-000029.Capital expenditure: $141.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-11-25, accession 0000879407-25-000029.Report this figure157Free cash flow, FY2025, twelve months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: $179.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-11-25, accession 0000879407-25-000029.Capital expenditure: $22.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-11-25, accession 0000879407-25-000029.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Dec 2024 to Nov 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Arrowhead Pharmaceuticals, Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
BlackRock, Inc.2026-06-30$1.21bn14,830,553Reduced−3,330,966
Avoro Capital Advisors LLC2026-06-30$925.6m11,355,555Added+655,556
FMR LLC2026-06-30$655.3m8,039,804Added+773,152
VANGUARD PORTFOLIO MANAGEMENT LLC2026-06-30$517.7m6,351,355Reduced−794,781
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$498.1m6,110,953Added+78,537
STATE STREET CORP2026-06-30$464.2m5,694,640Reduced−801,490
NORGES BANK2026-06-30$317.6m3,896,536New+3,896,536
Invesco Ltd.2026-06-30$316.6m3,883,976Added+603,329
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$298.8m3,530,612Reduced−748,216
FRED ALGER MANAGEMENT, LLC2026-06-30$269.1m3,301,919Reduced−40,574

Recent filings

All 1,081 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Arrowhead Pharmaceuticals, Inc., recent filings
FiledFormWhat it isAccession number
2026-08-0416:03 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0000879407-26-000058
2026-08-0416:02 ET10-QQuarterly reportPeriod 2026-06-300000879407-26-000057
2026-06-1616:02 ET8-K5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits0000879407-26-000050
2026-05-0716:05 ET10-QQuarterly reportPeriod 2026-03-310000879407-26-000047
2026-05-0716:02 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0000879407-26-000045
2026-03-2016:05 ET8-K5.07 Shareholder vote results; 9.01 Financial statements and exhibits0000879407-26-000037
2026-02-0516:06 ET10-QQuarterly reportPeriod 2025-12-310000879407-26-000034
2026-02-0516:05 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0000879407-26-000033
2026-01-2717:32 ETDEF 14AProxy statementPeriod 2026-01-260000879407-26-000019
2026-01-1217:00 ET8-K1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits0001193125-26-010582

Latest annual report

Form 10-K for the fiscal year ended Sep 30, 2025Filed Nov 25, 2025. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q4 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
879407
Tickers
ARWR
Exchange
Nasdaq
SIC code
2834 Pharmaceutical Preparations
Sector
Healthcare
Fiscal year ends
Sep 30
Incorporated in
DE
Filer category
Large accelerated filer
Former names
ARROWHEAD RESEARCH CORP (to 2016-04-06); INTERACTIVE GROUP INC (to 2004-01-09); INTERACTIVE INC (to 2002-02-13)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:26 ET. Listed shows no prices and gives no investment advice.